A dose-ranging study found age-related differences in remimazolam amounts required to reach a BIS endpoint. The result depended on an accompanying opioid and did not measure plasma exposure.
The endpoint and design
Patients undergoing gynecologic day procedures received one of four remimazolam dose levels together with sufentanil. Successful induction was defined as BIS below sixty within five minutes. The estimated ED95 was lower in the older cohort than in younger patients.
Hypotension was more frequent in older patients, while several other event comparisons were not significant. Thus a lower estimated effective dose did not eliminate observed vulnerability.
A model endpoint is not full recovery evidence
The estimates concern a processed-EEG threshold, not a direct test of memory, surgical awareness, or later safe function. Plasma and effect-site concentrations were not measured, limiting separation of pharmacokinetic from pharmacodynamic explanations.
The population was mainly lower-risk elective patients. The authors did not evaluate ongoing operative requirements or postoperative recovery and noted possible unrecognized airway obstruction.
Practical significance
Keep age group, co-administered sufentanil, observation time, and response definition attached to the result. An ED95 is a population model estimate with uncertainty. It is neither a patient-specific instruction nor a boundary that proves excessive or inadequate anesthesia in an individual case.
Source paper
Original analysis of the supplied journal article, identified as PMC12540430.
Leave a Reply